ReviewJournal of surgical oncology2019
Identification of risk in cutaneous melanoma patients: Prognostic and predictive markers.
Review in Journal of surgical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Melanoma Intelligence: Explainable AI Reveals Histopathologic Aggressiveness as the Dominant Axis of Lymph-Node Metastasis.Journal of clinical medicine · 2026Article
- A qualitative prognostic biomarker for melanoma based on the relative methylation orderings of CpG loci.Epigenetics · 2025Article
- METTL9 as a protein biomarker predicts the prognosis and immunotherapy response of skin-cutaneous melanoma.Annals of medicine and surgery (2012) · 2025Article
- Pair-matched analysis of Circulating Melanoma Cells (CMCs) before and after Immunotherapy in Relation to other Melanoma-Specific Biomarkers.Journal of Cancer · 2025Article
- An artificial intelligence-based model exploiting H&E images to predict recurrence in negative sentinel lymph-node melanoma patients.Journal of translational medicine · 2024Article
- 5-Methylcytosine immunohistochemistry for predicting cutaneous melanoma prognosis.Scientific reports · 2024Article
- Correlation Studies between S100 Protein Level and Soluble MIA or Tissue MelanA and gp100 (HMB45) Expression in Cutaneous Melanoma.Journal of personalized medicine · 2023Article
- Article
- Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha.Frontiers in oncology · 2023Article
- A deep learning model based on whole slide images to predict disease-free survival in cutaneous melanoma patients.Scientific reports · 2022Article
- Risk Stratification of Patients with Stage I Cutaneous Melanoma Using 31-Gene Expression Profiling.The Journal of clinical and aesthetic dermatology · 2021Review
- The human melanoma proteome atlas-Defining the molecular pathology.Clinical and translational medicine · 2021Article
- Expression ofCancers · 2021Article
- BRAF Gene and Melanoma: Back to the Future.International journal of molecular sciences · 2021Review
- Using Immune-Related lncRNA Signature for Prognosis and Response to Immunotherapy in Cutaneous Melanoma.International journal of general medicine · 2021Article
- Prognostic Value and Immunological Characteristics of a Novel RNA Binding Protein Signature in Cutaneous Melanoma.Frontiers in genetics · 2021Article
- Cost-Benefit Implication of Gene Expression Profiling and Adjuvant Therapy in Stage IIIA Melanoma.Journal of the American College of Surgeons · 2020Article
- Identification of CD38 as a potential biomarker in skin cutaneous melanoma using bioinformatics analysis.Oncology letters · 2020Article
- Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
New therapeutic modalities for melanoma promise benefit in selected individuals. Efficacy appears greater in patients with lower tumor burden, suggesting an important role for risk-stratified surveillance. Robust predictive markers might permit optimization of agent to patient, while low-risk prognostic markers might guide more conservative management. This review evaluates protein, gene, and multiplexed marker panels that may contribute to better risk assessment and improved management of patients with cutaneous melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.